Stockscreener 앱 받기
10.28
3.38%
-0.36
시간 외 거래:
10.27
-0.010
-0.10%
전일 마감가:
$10.64
열려 있는:
$10.71
하루 거래량:
1.65M
Relative Volume:
0.51
시가총액:
$1.66B
수익:
$68.56M
순이익/손실:
$-437.99M
주가수익비율:
-3.2492
EPS:
-3.1639
순현금흐름:
$-396.61M
1주 성능:
-5.08%
1개월 성능:
+22.38%
6개월 성능:
+59.88%
1년 성능:
+68.52%
1일 변동 폭
$10.17
$10.90
1주일 범위
$10.00
$10.96
52주 변동 폭
$4.155
$11.66
비르 바이오테크 Stock (VIR) Company Profile
명칭
Vir Biotechnology Inc
전화
415-906-4324
주소
1800 OWENS STREET, SAN FRANCISCO, CA
Compare VIR vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VIR
Vir Biotechnology Inc
|
10.28 | 1.72B | 68.56M | -437.99M | -396.61M | -3.1639 |
VRTX
Vertex Pharmaceuticals Inc
|
430.14 | 108.36B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
731.77 | 78.05B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
775.03 | 48.74B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
302.11 | 41.16B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
298.16 | 33.17B | 5.36B | 287.73M | 924.18M | 2.5229 |
비르 바이오테크 Stock (VIR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-24 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2025-09-03 | 개시 | Evercore ISI | Outperform |
| 2025-08-27 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-01-29 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2023-09-08 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-03-06 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-02-21 | 업그레이드 | Goldman | Neutral → Buy |
| 2023-01-27 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2022-09-14 | 개시 | SVB Leerink | Outperform |
| 2022-09-09 | 개시 | Morgan Stanley | Underweight |
| 2022-03-03 | 업그레이드 | Robert W. Baird | Underperform → Neutral |
| 2021-12-21 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2021-10-25 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-09-22 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-06-04 | 재개 | Robert W. Baird | Neutral |
| 2021-01-27 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2021-01-20 | 재확인 | H.C. Wainwright | Buy |
| 2020-10-05 | 개시 | BofA Securities | Buy |
| 2020-09-14 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-09-11 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2020-08-20 | 개시 | Needham | Buy |
| 2020-03-19 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2020-03-13 | 다운그레이드 | Goldman | Buy → Neutral |
| 2020-02-27 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2020-02-04 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-11-14 | 개시 | Robert W. Baird | Neutral |
| 2019-11-05 | 개시 | Barclays | Overweight |
| 2019-11-05 | 개시 | Cowen | Outperform |
| 2019-11-05 | 개시 | Goldman | Buy |
| 2019-11-05 | 개시 | JP Morgan | Overweight |
모두보기
비르 바이오테크 주식(VIR)의 최신 뉴스
Needham Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Vir Biotechnology prices $150M stock offering - MSN
Brii Bio reports durable HCB control in Phase II analysis - The Pharma Letter
Vir Biotechnology launches $200M public stock offering - MSN
Certain Stock options of Vir Biotechnology, Inc. are subject to a Lock-Up Agreement Ending on 27-APR-2026. - marketscreener.com
Is VIR a Good Stock to Buy? - HarianBasis.co
Is Vir Biotechnology, Inc. (VIR) A Good Stock To Buy Now? - Insider Monkey
Vir Biotechnology to Host Conference Call for First Quarter 2026 Financial Results - BioSpace
Press Release: Vir Biotechnology to Host Conference Call for First Quarter 2026 Financial Results - 富途牛牛
Vir Biotechnology to release Q1 2026 earnings on May 6 ahead of investor call - Traders Union
Vir Biotechnology Marks Key Hepatitis B Milestone With Phase 2 Combo Study Update - TipRanks
Vir Biotechnology Expands Oncology Pipeline via Astellas Partnership - HarianBasis.co
Vir Biotechnology (VIR) Posts 80.98% Year-To-Date Growth - Insider Monkey
VIR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Vir Biotechnology (VIR) Is Up 19.1% After Astellas Cancer Pact Closes With $315M Inflows - simplywall.st
Vir Biotechnology Doses First Patient in Prostate Cancer Clinical Trial - HarianBasis.co
Vir Biotechnology stock hits 52-week high at $10.94 By Investing.com - Investing.com Australia
Vir Biotechnology (NASDAQ:VIR) Sets New 1-Year HighHere's Why - MarketBeat
Can Vir Biotechnology (VIR)’s Masked T-Cell Technology Crack the Hardest-to-Treat Prostate Cancer? - insidermonkey.com
Vir Biotechnology stock hits 52-week high at $10.94 - Investing.com
Is Vir Biotechnology (VIR) One of the Best Low Priced Biotech Stocks to Invest In? - Insider Monkey
8 Best Low Priced Biotech Stocks to Invest In - Insider Monkey
Vir Biotechnology, Inc. ($VIR) CEO 2025 Pay Revealed - Quiver Quantitative
[ARS] Vir Biotechnology, Inc. SEC Filing - Stock Titan
Sanofi (SNY) Benefits from Vir Biotechnology's Collaboration wit - GuruFocus
Vir Biotechnology closes $240M Astellas deal for cancer drug By Investing.com - Investing.com Australia
Vir Biotechnology, Inc. Receives $240 Million Upfront Payment and $75 Million Equity Investment from Astellas - marketscreener.com
Vir Biotechnology Announces Closing of Global Strategic Collaboration with Astellas for the Treatmen - PharmiWeb.com
Vir Biotechnology Completes Astellas Deal to Advance Prostate Cancer Immunotherapy - Contract Pharma
Vir Biotechnology (NASDAQ: VIR) sets 2026 meeting and pay vote - Stock Titan
Vir Biotechnology closes $240M Astellas deal for cancer drug - Investing.com
Vir Biotechnology closes $240 million Astellas collaboration deal - StreetInsider
Vir Biotechnology Announces Closing of Global Strategic Collaboration with Astellas for the Treatment of Prostate Cancer - Business Wire
Vir Biotechnology Rings the Nasdaq Stock Market Closing Bell - Nasdaq
Vir Biotechnology Rings the Closing Bell - Nasdaq
A Look At Vir Biotechnology (VIR) Valuation After New VIR-5500 Prostate Cancer Trial Milestone - Yahoo Finance
VIR SEC FilingsVir Biotechnology, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Vir Biotechnology Announces First Patient Dosed in Phase 1 Dose-expansion Cohorts Evaluating PSMA-targeted, PRO-XTEN® Dual-masked T-cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer - BioSpace
Vir Biotechnology Q1 2025 Earnings Preview - MSN
Vir Biotechnology doses first patient in VIR-5500 expansion trial By Investing.com - Investing.com Australia
Vir Biotechnology (VIR) Advances Phase 1 Trial with First Patien - GuruFocus
Vir Biotechnology Announces First Patient Dosed in Phase 1 Dose-expansion Cohorts Evaluating PSMA-ta - PharmiWeb.com
Vir Biotechnology doses first patient in VIR-5500 expansion trial - Investing.com
Vir Biotech CEO Stock Sale: $664K Transaction in April 2026News and Statistics - IndexBox
Vir Biotechnology (VIR) CEO Sells 73,000 Shares for $664,000 - AOL.com
비르 바이오테크 (VIR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.29%
0.00%
자본화:
|
볼륨(24시간):